Nkarta (NASDAQ:NKTX – Get Rating) had its target price reduced by Mizuho from $81.00 to $26.00 in a research note issued to investors on Wednesday morning, The Fly reports. Mizuho currently has a buy rating on the stock.
Several other equities analysts also recently weighed in on NKTX. Needham & Company LLC began coverage on shares of Nkarta in a research note on Thursday, July 28th. They issued a buy rating and a $26.00 target price for the company. Canaccord Genuity Group initiated coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 price objective for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Oppenheimer reduced their price objective on shares of Nkarta from $50.00 to $36.00 and set an outperform rating for the company in a research note on Thursday, November 10th. Finally, Canaccord Genuity Group initiated coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta presently has a consensus rating of Buy and a consensus price target of $30.90.
Nkarta Stock Down 3.6 %
NKTX opened at $9.32 on Wednesday. The company has a market capitalization of $454.91 million, a price-to-earnings ratio of -3.49 and a beta of 0.13. The firm has a 50-day moving average price of $12.55 and a 200-day moving average price of $13.55. Nkarta has a twelve month low of $7.55 and a twelve month high of $20.35.
Insiders Place Their Bets
Institutional Investors Weigh In On Nkarta
A number of hedge funds have recently made changes to their positions in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the 2nd quarter worth approximately $31,000. Quantbot Technologies LP lifted its holdings in shares of Nkarta by 39.1% in the 1st quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock worth $36,000 after acquiring an additional 900 shares during the last quarter. Denali Advisors LLC bought a new stake in shares of Nkarta in the 2nd quarter worth approximately $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the 3rd quarter worth approximately $46,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock worth $54,000 after acquiring an additional 4,147 shares during the last quarter.
Nkarta Company Profile
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.